FGF21-based pharmacotherapy - potential utility for metabolic disorders

Trends in Endocrinology and Metabolism

Volumn 25, Issue 6, 2014, Pages 303-311

  Gimeno, Ruth E ^a   Moller, David E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; ARX 618; C 3201 HSA; CORTICOTROPIN; CVX 343; FATTY ACID; FC FGF 21; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 21 RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GLUCAGON; GLUCOSE; GROWTH FACTOR; GROWTH HORMONE; GW 590735; INSULIN; KLB PROTEIN; LIPID; LY 2405319; MESSENGER RNA; PEG FGF 21; PEGDINETANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECOMBINANT FIBROBLAST GROWTH FACTOR 21; RECOMBINANT GROWTH FACTOR; ROSIGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; FIBROBLAST GROWTH FACTOR;

ADIPOCYTE; ADIPOSE TISSUE; BRAIN; BRAIN STEM; CIRCADIAN RHYTHM; DIET RESTRICTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENDOPLASMIC RETICULUM STRESS; ENERGY EXPENDITURE; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; HYPOTHALAMUS; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LIVER; METABOLIC DISORDER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OVERNUTRITION; PANCREAS; PRIMATE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; STARVATION; ANIMAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENERGY METABOLISM; LIPID METABOLISM; METABOLIC DISEASES; METABOLISM;

ANIMALS; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; FIBROBLAST GROWTH FACTORS; HUMANS; LIPID METABOLISM; METABOLIC DISEASES;

EID: 84901821975     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.03.001     Document Type: Review

References (82)

1. Kharitonenkov A., et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005, 115:1627-1635.
2. Coskun T., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
3. Xu J., et al. Fibroblast growth factor-21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
4. Xu J., et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models - association with liver and adipose tissue effects. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E1105-E1114.
5. Hecht R., et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS ONE 2012, 7:e49345.
6. Veniant M.M., et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 2012, 153:4192-4203.
7. Berglund E.D., et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009, 150:4084-4093.
8. Kharitonenkov A., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
9. Kurosu H., et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 2007, 282:26687-26695.
10. Kharitonenkov A., et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol. 2008, 215:1-7.
11. Adams A.C., et al. FGF21 requires betaklotho to act in vivo. PLoS ONE 2012, 7:e49977.
12. Ding X., et al. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012, 16:387-393.
13. Yie J., et al. Understanding the physical interactions in the FGF21/FGFR/beta-Klotho complex: structural requirements and implications in FGF21 signaling. Chem. Biol. Drug Des. 2012, 79:398-410.
14. Yang C., et al. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS ONE 2012, 7:e33870.
15. Tomiyama K., et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1666-1671.
16. Ge H., et al. Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS ONE 2012, 7:e33603.
17. Moyers J.S., et al. Molecular determinants of FGF-21 activity - synergy and cross-talk with PPARg signaling. J. Cell. Physiol. 2007, 210:1-6.
18. Fisher F.M., et al. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 2011, 152:2996-3004.
19. Adams A.C., et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2012, 2:31-37.
20. Ge X., et al. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J. Biol. Chem. 2011, 286:34533-34541.
21. Chau M.D., et al. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:12553-12558.
22. Muise E.S., et al. Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21. PLoS ONE 2013, 8:e73011.
23. Potthoff M.J., et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:10853-10858.
24. Fisher F.M., et al. FGF21 regulates PGC-1a and browning of white adipose tissue in adaptive thermogenesis. Genes Dev. 2012, 26:271-281.
25. Muller T.D., et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J. Pept. Sci. 2012, 18:383-393.
26. Bookout A.L., et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat. Med. 2013, 19:1147-1152.
27. Foltz I.N., et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci. Transl. Med. 2012, 4:162ra153.
28. Lee P., et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab. 2014, 19:302-309.
29. Ye R., Scherer P.E. Adiponectin, driver or passenger on the road to insulin sensitivity?. Mol. Metab. 2013, 2:133-141.
30. Holland W.L., et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013, 17:790-797.
31. Lin Z., et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013, 17:779-789.
32. Muise E.S., et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor g and altered metiaolic states. Mol. Pharmacol. 2008, 74:403-412.
33. Dutchak P.A., et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
34. Adams A.C., et al. Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. Mol. Metab. 2013, 2:205-214.
35. Wente W., et al. Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal regulated-kinase 1/2 and Akt signaling. Diabetes 2006, 55:2470-2478.
36. Mu J., et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 2012, 61:505-512.
37. Huang J., et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J. Pharmacol. Exp. Ther. 2013, 346:270-280.
38. Sarruf D.A., et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 2010, 59:1817-1824.
39. Tan B.K., et al. Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity. Diabetes 2011, 60:2758-2762.
40. Hsuchou H., et al. The fasting polypeptide FGF21 can enter brain from blood. Peptides 2007, 28:2382-2386.
41. Leng Y., et al. FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is markedly elevated in neurons by mood stabilizers. Mol. Psychiatry 2014, 10.1038/mp.2013.192.
42. Owen B.M., et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat. Med. 2013, 19:1153-1156.
43. Badman M.K., et al. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009, 150:4931-4940.
44. Hotta Y., et al. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 2009, 150:4625-4633.
45. Inagaki T., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5:415-425.
46. Badman M.K., et al. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007, 5:426-437.
47. Inagaki T., et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF-21. Cell Metab. 2008, 8:1-7.
48. Wu S., et al. Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate. J. Biol. Chem. 2012, 287:26060-26067.
49. Bartke A., Brown-Borg H. Life extension in the dwarf mouse. Curr. Top. Dev. Biol. 2004, 63:189-225.
50. Zhang Y., et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife 2012, 1:e00065.
51. Fisher F.M., Maratos-Flier E. Stress heats up the adipocyte. Nat. Med. 2013, 19:17-18.
52. Fisher F.M., et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010, 59:2781-2789.
53. Kim K.H., et al. Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS ONE 2013, 8:e63517.
54. Kim K.H., et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing FGF21 as a mitokine. Nat. Med. 2013, 19:83-92.
55. Schaap F.G., et al. Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. Biochimie 2013, 95:692-699.
56. Johnson C.L., et al. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 2009, 137:1795-1804.
57. Galman C., et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 2008, 8:169-174.
58. Hager T., et al. Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. Anal. Chem. 2013, 85:2731-2738.
59. Dushay J., et al. Increased fibroblast growth factor 21 in obesity and nonalchoholic fatty liver disease. Gastroenterology 2010, 139:456-463.
60. Xiao Y., et al. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J. Clin. Endocrinol. Metab. 2012, 97:E54-E58.
61. Bobbert T., et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care 2013, 36:145-149.
62. Chen C., et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011, 34:2113-2115.
63. Andersen B., et al. Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers. Clin. Endocrinol. (Oxf.) 2011, 75:514-519.
64. Christodoulides C., et al. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J. Clin. Endocrinol. Metab. 2009, 94:3594-3601.
65. Heilbronn L.K., et al. Metabolically protective cytokines adiponectin and fibroblast growth factor 21 are increased by acute overfeeding in healthy humans. PLoS ONE 2013, 8:e78864.
66. Mai K., et al. Physiological modulation of circulating FGF21: relevance of free fatty acids and insulin. Am. J. Physiol. 2010, 299:E126-E130.
67. Hojman P., et al. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 2009, 58:2797-2801.
68. Kharitonenkov A., et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY-2405319. PLoS ONE 2013, 8:e58575.
69. Adams A.C., et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS ONE 2013, 8:e65763.
70. Xu J., et al. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation. Bioconjug. Chem. 2013, 24:915-925.
71. Mukherjee R., et al. FGF21-adnectin-pharmacokinetic enhancer (FGF21-AdPKE): a novel protein candidate with uniquely extended pharmacokinetic profile for the treatment of diabetes and dyslipidemia. American Diabetes Association 72nd Scientific Sessions Oral Presentation 2012, 288-OR.
72. Wu A.L., et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci. Transl. Med. 2011, 3:113ra126.
73. Smith R., et al. FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/beta-Klotho bispecific protein. PLoS ONE 2013, 8:e61432.
74. Habegger K.M., et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 2013, 62:1453-1463.
75. Arafat A.M., et al. Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?. Diabetologia 2013, 56:588-597.
76. Gaich G., et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013, 18:333-340.
77. Zheng C., et al. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 2010, 121:1722-1734.
78. Wei W., et al. Fibroblast growth factor-21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3143-3148.
79. Lee P., et al. Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans?. Osteoporos. Int. 2013, 24:3053-3057.
80. Yie J., et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett. 2009, 583:19-24.
81. Ogawa Y., et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:7432-7437.
82. Camacho R.C., et al. Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice. Eur. J. Pharmacol. 2013, 715:41-45.